LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific consultancy company, specializing in bioanalytical and biosample project management, biomarker strategy and logistics solutions in support of pre-clinical and clinical trials. The combined international team brings an unparalleled breadth and depth of technical and scientific expertise to help clients successfully achieve pre-clinical and clinical trial objectives sooner.
A4P is headquartered in Discovery Park, Sandwich, Kent, UK, with a wholly-owned subsidiary in Appenzell, Switzerland. With core expertise in regulated bioanalysis and genomics, biomarker strategy, personalized healthcare, biosample operations and bespoke logistics solutions, A4P serves a wide variety of clients across a broad range of therapeutic areas.
“A4P was founded over 12 years ago by four individuals from the pharma industry with a vision of how Bioanalytical and Logistical consultancy could be transformed,” said Ian James, PhD., Co-Founder and Chief Executive Officer of A4P. “Bringing together our unique company model with LabConnect unlocks exciting opportunities to broaden the geographies we operate in and enhance our service offerings for our customers. I am excited for the future for both our customers and our valued staff.”
Also Read: CSafe Elevates Cell and Gene Therapy Transport with Reusable Cryogenic Solution
Partnering with pharmaceutical and biotechnology companies, contract research organizations (CROs), and foundations/non-governmental organizations (NGOs), LabConnect provides innovative Central Laboratory Services and scientific Functional Service Provider (FSP) Solutions for clinical trials of all sizes and complexity across the globe. As the requirements for clinical trials and the drug development process have become more complex, LabConnect meets these requirements by offering researchers scientific and technical expertise for all laboratory-related needs, advising on strategies for lab data collection and providing end-to-end analytical and logistical solutions tailored to each trial.
This acquisition further solidifies LabConnect’s industry leading position as a provider of global central laboratory services and scientific-focused FSP Solutions.
“With our complementary experience, expertise, and nimble working model, our clients have unprecedented access to leading edge scientific solutions to support their pre-clinical and clinical research,” said Dawn Sherman, Chief Executive Officer of LabConnect. “By joining forces with A4P, we further our mission to create healthier communities and improve patient lives by accelerating the development of medicines.”
SOURCE: PRNewswire